These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

472 related articles for article (PubMed ID: 27664755)

  • 1. T-cell immunometabolism against cancer.
    Jiang S; Yan W
    Cancer Lett; 2016 Nov; 382(2):255-258. PubMed ID: 27664755
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolic reprogramming in the tumour microenvironment: a hallmark shared by cancer cells and T lymphocytes.
    Allison KE; Coomber BL; Bridle BW
    Immunology; 2017 Oct; 152(2):175-184. PubMed ID: 28621843
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolic Barriers to T Cell Function in Tumors.
    Sugiura A; Rathmell JC
    J Immunol; 2018 Jan; 200(2):400-407. PubMed ID: 29311381
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treg programming and therapeutic reprogramming in cancer.
    Moreno Ayala MA; Li Z; DuPage M
    Immunology; 2019 Jul; 157(3):198-209. PubMed ID: 30866047
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunometabolism: A new target for improving cancer immunotherapy.
    Guo C; Chen S; Liu W; Ma Y; Li J; Fisher PB; Fang X; Wang XY
    Adv Cancer Res; 2019; 143():195-253. PubMed ID: 31202359
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolic reprograming of anti-tumor immunity.
    Sukumar M; Kishton RJ; Restifo NP
    Curr Opin Immunol; 2017 Jun; 46():14-22. PubMed ID: 28412583
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differentiation and Regulation of T
    Basu A; Ramamoorthi G; Albert G; Gallen C; Beyer A; Snyder C; Koski G; Disis ML; Czerniecki BJ; Kodumudi K
    Front Immunol; 2021; 12():669474. PubMed ID: 34012451
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting T cell metabolism for immunotherapy.
    Gao J; Liu Y; Wei J; Jiang L; Mao J; Chang CH; Wu D
    J Leukoc Biol; 2021 Dec; 110(6):1081-1090. PubMed ID: 34779530
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunomodulation in cancer.
    Hegmans JP; Aerts JG
    Curr Opin Pharmacol; 2014 Aug; 17():17-21. PubMed ID: 25011112
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevailing over T cell exhaustion: New developments in the immunotherapy of pancreatic cancer.
    Bauer C; Kühnemuth B; Duewell P; Ormanns S; Gress T; Schnurr M
    Cancer Lett; 2016 Oct; 381(1):259-68. PubMed ID: 26968250
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antitumor T-cell Reconditioning: Improving Metabolic Fitness for Optimal Cancer Immunotherapy.
    Rivadeneira DB; Delgoffe GM
    Clin Cancer Res; 2018 Jun; 24(11):2473-2481. PubMed ID: 29386217
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor-derived ILT4 induces T cell senescence and suppresses tumor immunity.
    Gao A; Liu X; Lin W; Wang J; Wang S; Si F; Huang L; Zhao Y; Sun Y; Peng G
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33653799
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tissue-resident memory-like T cells in tumor immunity: Clinical implications.
    Dhodapkar MV; Dhodapkar KM
    Semin Immunol; 2020 Jun; 49():101415. PubMed ID: 33011063
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integrating T cell metabolism in cancer immunotherapy.
    Dugnani E; Pasquale V; Bordignon C; Canu A; Piemonti L; Monti P
    Cancer Lett; 2017 Dec; 411():12-18. PubMed ID: 28974448
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD147‑mediated reprogrammed glycolytic metabolism potentially induces immune escape in the tumor microenvironment (Review).
    Li X; Xu W
    Oncol Rep; 2019 May; 41(5):2945-2956. PubMed ID: 30864716
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune-mediated anti-tumor effects of metformin; targeting metabolic reprogramming of T cells as a new possible mechanism for anti-cancer effects of metformin.
    Bahrambeigi S; Shafiei-Irannejad V
    Biochem Pharmacol; 2020 Apr; 174():113787. PubMed ID: 31884044
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of Mitochondria in Cancer Immune Evasion and Potential Therapeutic Approaches.
    Klein K; He K; Younes AI; Barsoumian HB; Chen D; Ozgen T; Mosaffa S; Patel RR; Gu M; Novaes J; Narayanan A; Cortez MA; Welsh JW
    Front Immunol; 2020; 11():573326. PubMed ID: 33178201
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Harnessing Metabolic Reprogramming to Improve Cancer Immunotherapy.
    Yan L; Tan Y; Chen G; Fan J; Zhang J
    Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638609
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting T cell metabolism in the tumor microenvironment: an anti-cancer therapeutic strategy.
    Yin Z; Bai L; Li W; Zeng T; Tian H; Cui J
    J Exp Clin Cancer Res; 2019 Sep; 38(1):403. PubMed ID: 31519198
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulatory T cells in cancer; can they be controlled?
    Adeegbe DO; Nishikawa H
    Immunotherapy; 2015; 7(8):843-6. PubMed ID: 26316166
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 24.